0000000000885342

AUTHOR

D. Rodriguez Abreu

Tobacco use in lung cancer (LC) patients (p) in Spain

Abstract Background Tobacco use, mainly as cigarette smoking, is the leading cause of lung cancer. Eighty-five percent of LC occur in smokers. Understanding the Spanish smoking habits allows the government to design health care policies against this consumption. To do so, the Grupo Espanol de Cancer de Pulmon (Spanish Lung Cancer Group) made this analysis within the context of the Thoracic Tumor Registry (TTR). Methods The TTR is an observational cohort multicenter study in Spain. The study is conducted according to the Declaration of Helsinki and approved by the institutional review board of each participating site. The registry was approved by the Spanish Drug Agency, as a non-post-author…

research product

Biomarker testing of lung cancer in Spain

Abstract Background Target therapy guide by biomarkers have become the standard of care for patients with lung cancer (LC). So, identify those molecular alterations is one of the most important care needs nowdays. Our objective was to know the implementation degree of these tests in a large cohort of patients in Spain using the Thoracic Tumor Registry (TTR) of the Grupo Espanol de Cancer de Pulmon (Spanish Lung Cancer Group). Methods The TTR is an observational cohort multicenter study of LC in Spain. The study is conducted according to the Declaration of Helsinki and approved by the institutional review board of each participating institute. The registry was approved by the Spanish Drug Ag…

research product

Snps in Angiogenic Factors As Predictive Markers for Outcome in Patients (P) with Advanced Non-Squamous Nsclc (NS-NSCLC) Treated with Carboplatin, Paclitaxel (CP) and Bevacizumab (BEV). Final Results of Angiomet Spanish Lung Cancer Group Trial

research product